Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.

van Gorp, Anne-Marie; Rolfes, Leàn; Härmark, Linda; van der Horst, Petra; Hendriks, Judith; Vorstenbosch, Saskia

van Gorp, Anne-Marie; Rolfes, Leàn; Härmark, Linda; van der Horst, Petra; Hendriks, Judith; Vorstenbosch, Saskia.

Afiliação

van Gorp AM; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Rolfes L; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Härmark L; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
van der Horst P; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Hendriks J; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Vorstenbosch S; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.

Pharmacoepidemiol Drug Saf ; 29(12): 1588-1595, 2020 12.

Article em En | MEDLINE | ID: mdl-32854158

Assuntos

Diabetes Mellitus Tipo 2; Inibidores da Dipeptidil Peptidase IV; Diabetes Mellitus Tipo 2/tratamento farmacológico; Inibidores da Dipeptidil Peptidase IV/efeitos adversos; Dipeptidil Peptidases e Tripeptidil Peptidases; Peptídeo 1 Semelhante ao Glucagon; Receptor do Peptídeo Semelhante ao Glucagon 1; Humanos; Hipoglicemiantes/efeitos adversos; Estudos Prospectivos

Palavras-chave

DPP-4 inhibitors; GLP-1 agonists; adverse drug reactions; antidiabetics; pharmacoepidemiology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google